Not to mention the fact that no other trials (ongoing or planned) were mentioned in either the press release or conference call. Enough said.
Clearly, the pooled data is a nonstarter for approval
Opinions and comments may have been previously posted @BioDueDiligence, at www.biotechduediligence.com, or disseminated to Chimera Research Group subscribers.